RecruitingNot ApplicableNCT07559201

Theranostic Applications of Radionuclides in Prostate Cancer

ACP3 Targeted -PET/ CT in Prostate Cancer

Sponsor

Guilin Medical University, China

Enrollment

100 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer (Diagnosis)

Summary

The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.

Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria4

Adult patients (aged 18 years or older);
Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans;
Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria1

The inability or unwillingness of the research participant or legal representative to provide written informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTstandard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (PSMA/FDG) and ACP3, and undergoes PET/CT imaging within the specified time.